Search results
AXS Relaunches HYLD Fund to Focus on Mortgage REITs
etf.com via Yahoo Finance· 8 months agoAXS Investments relaunched a high-yield ETF as a mortgage REIT exchange-traded fund, aiming to entice investors back to an investment whose reputation...
AXS or BRK.B: Which Is the Better Value Stock Right Now?
Zacks via Yahoo Finance· 8 months agoInvestors with an interest in Insurance - Property and Casualty stocks have likely encountered both...
AXIS Capital (AXS) Q3 Earnings Miss Estimates, Increase Y/Y
Zacks via Yahoo Finance· 2 years agoAXIS Capital's (AXS) Q3 results reflect higher net premiums earned and lower expenses, partially...
AXS vs. ALL: Which Stock Is the Better Value Option?
Zacks via Yahoo Finance· 11 months agoInvestors interested in stocks from the Insurance - Property and Casualty sector have probably already heard of Axis Capital (AXS) and Allstate (ALL)....
Here's Why You Should Add AXIS Capital (AXS) to Portfolio Now?
Zacks via Yahoo Finance· 1 year agoAXIS Capital Holdings Limited‘s AXS focus on expansion into new verticals, the increasing popularity...
Here's Why Investors Should Buy AXIS Capital (AXS) Stock Now
Zacks via Yahoo Finance· 1 month agoAXIS Capital (AXS) remains well-poised to gain from higher net investment income, strong market...
AXS vs. TKOMY: Which Stock Should Value Investors Buy Now?
Zacks via Yahoo Finance· 1 year agoInvestors with an interest in Insurance - Property and Casualty stocks have likely encountered both...
Think Tesla's Going Down More? New ETF Rises When Tesla Falls
Investor's Business Daily· 2 years agoLooking for more ways to play Tesla stock? In a U.S. industry first, AXS Investments has introduced...
AXS or RLI: Which P&C Insurance Stock is Better Placed?
Zacks via Yahoo Finance· 2 years agoBetter pricing, an improving rate environment, exposure growth, prudent underwriting and solid...
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
Zacks via Yahoo Finance· 2 years agoAxsome AXSM announced the enrollment of the first patient in the EMERGE phase III open label study...